INFORMATION ABOUT THE ISSUER 5 5.1 5.1.3.2 Duration HISTORY AND DEVELOPMENT The Company’s duration is 99 years from the date of its registration with the Paris Trade and Companies Register except 5.1.1 COMPANY NAME in the event of early dissolution or extension. Our corporate name is “GenSight Biologics S.A.” 5.1.4 REGISTERED OFFICE, LEGAL FORM AND 5.1.2 PLACE OF REGISTRATION AND REGISTRATION APPLICABLE LEGISLATION NUMBER 5.1.4.1 Registered office We are registered with the Paris Trade and Companies Register Our registered office is located at 74, rue du Faubourg Saint- under number 751 164 757. Antoine – 75012 Paris, France (Tel: +33 (0)1 76 21 72 20). 5.1.3 DATE OF INCORPORATION AND DURATION 5.1.4.2 Legal form and applicable legislation We are a French limited liability corporation (société anonyme) 5.1.3.1 Date of incorporation of the Company with a Board of Directors, governed by French law, including, in We were incorporated on April 17, 2012. particular, Book I I of the French Commercial Code. 5.1.5 IMPORTANT EVENTS IN THE DEVELOPMENT OF THE COMPANY April 2012 Incorporation of the Company on the basis of a collaborative effort involving renowned academic institutions. March 2013 Series A private round raising €19.7 million through Novartis Venture Fund, Abingworth, Versant Ventures, Vitavest S.à r.l. and Bpifrance (FBIMR). February 2014 Initiation of a Phase I/I I clinical trial to assess safety and tolerability of GS010 in Leber’s Hereditary Optic Neuropathy, or LHON. June 2015 Positive interim safety report of the Phase I/I I clinical trial confirming safety and tolerability of GS010 in LHON. July 2015 Series B private round raising €32.1 million (or €30.8 million net proceeds) through our Series A investors joined by Fidelity Management & Research Company, Perceptive Advisors, Jennison Associates, HealthCap and Sphera Global HealthCare Fund. December 2015 Initiation of two Phase I I I clinical trials to demonstrate efficacy of GS010 in LHON. July 2016 Listing of our shares on Euronext Paris which allowed the Company to raise approximately €45.2 million (or €41.4 million net proceeds). January 2017 U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa. April 2017 Creation of the first subsidiary, GenSightBiologics Inc., registered and located in the Unites States of America. June 2017 Capital Increase which allowed to raise €22.5 milion (or €20.7 million net proceeds), by means of a private placement reserved to a category of persons, U.S. and European institutional investors specialized in healthcare and biotechnology. December 2017 Positive long-term visual acuity gains and safety results from Phase I/I I Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy. December 2017 GenSight Biologics received MHRA approval to initiate Phase I/I I PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa. April 2018 Topline data of the REVERSE Phase I I I clinical trial with GS010 in LHON. 62 – GENSIGHT BIOLOGICS – 2017 Registration Document